Contract 75A50122C00065
Amgen USA Inc · Department Of Health And Human Services · September 28, 2022
Amgen USA Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 28, 2022 for $569.02 million of work in research and development in biotechnology (except nanobiotechnology). Performance is in Newbury Park, CA. It was awarded under full and open competition. The contract has been modified 4 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on March 6, 2026. If all options are exercised, the contract could reach $916.70 million.
Contract details
- PIID
- 75A50122C00065
- Award type
- Definitive Contract
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
- Product / service
- Health R&D Services; Health Care Services; Experimental Development
- Place of performance
- Newbury Park, CA
- First action
- September 28, 2022
- Latest action
- March 6, 2026
Description
EXERCISE OPTION PERIOD 4 AND MODIFY THE NUMBER OF DOSES. CHANGE THE PERIOD OF PERFORMANCE TO MARCH 4, 2026 THROUGH SEPTEMBER 29, 2032. THE TOTAL CONTRACT FUNDED VALUE INCREASED FROM $713,890,168.42 BY $59,988,838.10 TO $773,879,006.52.
Modification timeline
-
March 6, 2026Mod P00007 · Supplemental Agreement For Work Within Scope$773.88M
-
July 15, 2025Mod P00006 · Exercise An OptionEXERCISE OPTION PERIOD 3 CLINS 0010, 0011, AND 0012.$713.89M
-
September 27, 2024Mod P00005 · Other Administrative ActionREVISE OPTION PERIOD 2 CLINS 0007 - 0009 PERIOD OF PERFORMANCE.$623.92M
-
September 18, 2024Mod P00004 · Funding Only ActionEXERCISE OPTION PERIOD 2 CLINS 0007 - 0009 FOR THE PROCUREMENT OF 62,896 UNITS OF NPLATE PHARMACEUTICAL PRODUCTS.$623.92M
-
September 28, 2022Base awardTREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN.$494.92M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Vericel Corporation | Department Of Health And Human Services | April 1, 2026 | $34.88M |
| American College Of Medical Toxicology, Inc. | Department Of Health And Human Services | March 31, 2026 | $0 |
| Ceramedix Holding, Llc | Department Of Health And Human Services | March 31, 2026 | $4.22M |
| Glaxosmithkline, Llc | Department Of Health And Human Services | March 31, 2026 | $7.79M |
| Care Access Research Llc | Department Of Health And Human Services | March 31, 2026 | $2.55M |
| Pattern Bioscience, Inc. | Department Of Health And Human Services | March 31, 2026 | $22.50M |
Top contractors in NAICS 541714
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Amgen USA Inc | 1 | $59.99M |
| 2 | Vericel Corporation | 1 | $34.88M |
| 3 | Spectral Md, Inc. | 1 | $31.67M |
| 4 | Ppd Development Lp | 6 | $31.12M |
| 5 | L3 Technologies, Inc. | 1 | $22.00M |
| 6 | Technical Resources International, Inc. | 6 | $21.80M |
| 7 | Abbott Laboratories | 1 | $21.01M |
| 8 | Paratek Pharmaceuticals, Inc | 1 | $17.47M |
| 9 | Ossium Health, Inc. | 1 | $12.39M |
| 10 | Rho Federal Systems Division Inc | 1 | $8.00M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50122C00065?
Contract 75A50122C00065 is a federal contract awarded to Amgen USA Inc by Department Of Health And Human Services on September 28, 2022 for $569.02 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 4 times since the base award.
Who won contract 75A50122C00065?
Amgen USA Inc won contract 75A50122C00065 from Department Of Health And Human Services.
How much is contract 75A50122C00065 worth?
Contract 75A50122C00065 has obligated $569.02 million to date, with a total potential value of $916.70 million if all options are exercised.